The majority of tumors in BRCA1 mutation carriers are of the triple-negative subtype while over 70% of tumors among BRCA2 carriers are luminal-like, a similar proportion as in the general population of breast cancer patients4. This evidence concerns the gene BRCA2 and breast carcinoma.